NCT01725152View on ClinicalTrials.gov

Ganaxolone Treatment in Children With Fragile X Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

October 16, 2015

Study Completion Date

November 1, 2016

Conditions
Fragile x Syndrome
Interventions
DRUG

Ganaxolone

oral suspension, given in 3 divided doses

DRUG

Placebo

oral suspension, given in 3 divided doses

Trial Locations (2)

2650

Antwerp University Hospital, Edegem

95817

M.I.N.D. Institute at University of California at Davis Medical Center, Sacramento

Sponsors
All Listed Sponsors
collaborator

University of California, Davis

OTHER

collaborator

U.S. Army Medical Research and Development Command

FED

lead

Marinus Pharmaceuticals

INDUSTRY

NCT01725152 - Ganaxolone Treatment in Children With Fragile X Syndrome | Biotech Hunter | Biotech Hunter